Vaccinex Inc

NASDAQ:VCNX  
2.25
+0.02 (+0.90%)
Products, Regulatory

Vaccinex Says Pepinemab Was Well-Tolerated In Phase 2 SIGNAL Study

Published: 09/22/2020 12:07 GMT
Vaccinex Inc (VCNX) - Top-line Results of Phase 2 Signal Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab.
Vaccinex Inc - Results Support Continued Development in Alzheimer's Disease and in Mid-stage Huntington's Disease Patients With Greater Cognitive Deficits.
Vaccinex Inc - Overall Study Does Not Meet Pre-specified Co-primary Endpoints.
Vaccinex Inc - Key Cognitive Endpoints Trending Towards But Did Not Reach Statistical Significance in Early Manifest Population.
Vaccinex Inc - Pepinemab Was Well-tolerated.
Vaccinex - Expects to Begin Enrolling Patients This Month in a New Alzheimer's Disease Study of Pepinemab at 15 Clinical Sites in United States.